NEW YORK (GenomeWeb News) – The US Supreme Court today unanimously ruled that human genes are not patentable, but synthetic DNA, or cDNA, is patent eligible because it does not occur naturally.

The decision, written by Justice Clarence Thomas, was hailed by the plaintiffs in the case, Association for Molecular Pathology et al. v. Myriad Genetics, who view it as a victory for patients seeking greater access to genetic testing and researchers aiming to develop new molecularly guided personalized treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.